GW VitekLTD Past Earnings Performance
Past criteria checks 0/6
GW VitekLTD's earnings have been declining at an average annual rate of -2.3%, while the Life Sciences industry saw earnings growing at 15.5% annually. Revenues have been declining at an average rate of 2.4% per year.
Key information
-2.3%
Earnings growth rate
35.5%
EPS growth rate
| Life Sciences Industry Growth | 53.7% |
| Revenue growth rate | -2.4% |
| Return on equity | -55.4% |
| Net Margin | -52.2% |
| Last Earnings Update | 30 Sep 2024 |
Revenue & Expenses Breakdown
How GW VitekLTD makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 33,853 | -17,659 | 16,287 | 3,273 |
| 30 Jun 24 | 39,723 | -17,848 | 16,471 | 3,273 |
| 31 Mar 24 | 43,597 | -14,452 | 16,648 | 3,795 |
| 31 Dec 23 | 47,923 | -14,928 | 14,388 | 4,328 |
| 30 Sep 23 | 50,622 | -12,283 | 14,683 | 4,208 |
| 30 Jun 23 | 51,176 | -10,220 | 14,452 | 4,208 |
| 31 Mar 23 | 52,584 | -9,886 | 13,541 | 3,687 |
| 31 Dec 22 | 52,526 | -8,361 | 14,140 | 1,928 |
| 30 Sep 22 | 51,748 | -9,661 | 12,555 | 1,458 |
| 30 Jun 22 | 48,970 | -8,973 | 10,602 | 2,020 |
| 31 Mar 22 | 50,279 | -5,741 | 9,862 | 1,711 |
| 31 Dec 21 | 52,574 | -5,001 | 10,437 | 1,672 |
| 30 Sep 21 | 53,133 | -6,817 | 11,532 | 1,090 |
| 30 Jun 21 | 55,860 | -3,068 | 11,805 | 528 |
| 31 Mar 21 | 54,788 | -3,209 | 11,541 | 430 |
| 31 Dec 20 | 52,493 | -5,067 | 10,370 | 453 |
| 30 Sep 20 | 50,756 | -19,008 | 44,814 | 436 |
| 30 Jun 20 | 50,519 | -23,632 | 46,678 | 436 |
| 31 Mar 20 | 47,918 | -23,671 | 46,685 | 506 |
| 31 Dec 19 | 44,571 | -21,821 | 46,431 | 416 |
| 30 Sep 19 | 43,528 | 817 | 9,519 | 428 |
| 31 Dec 18 | 38,972 | 2,503 | 6,716 | 419 |
Quality Earnings: A036180 is currently unprofitable.
Growing Profit Margin: A036180 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A036180 is unprofitable, and losses have increased over the past 5 years at a rate of 2.3% per year.
Accelerating Growth: Unable to compare A036180's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A036180 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (18%).
Return on Equity
High ROE: A036180 has a negative Return on Equity (-55.4%), as it is currently unprofitable.